ALNY Alnylam Pharmaceuticals (ALNY) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001178670
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
413
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $789.8K priced
What the filings say about ALNY
Insiders, 180 days
-$1.5M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-05-12
Planned sales (Form 144), 90 days
$398.9K
1 notice
Alnylam Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ALNYLAM PHARMACEUTICALS, INC. insiders sold a net $1.5M of stock across 907 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 13.7% of the 12,807 shares held after it.
- No other insider sold within 30 days.
- 413 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CLO and Secretary SUPRAN BRYAN sold about $398.9K of ALNY on Oct 2, 2026; 413 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 24, 2025.
- The trade is 35.4% of the 3,316 shares held after it.
- No other insider sold within 30 days.
- 413 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PYOTT DAVID E I sold about $351.2K of ALNY on Jun 1, 2026; 413 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 24, 2025.
- The trade is 1.1% of the 1,582 shares held after it.
- No other insider sold within 30 days.
- 413 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PYOTT DAVID E I sold about $5.1K of ALNY on Jun 1, 2026; 413 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 24, 2025.
- The trade is 20.5% of the 4,491 shares held after it.
- No other insider sold within 30 days.
- 413 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PYOTT DAVID E I sold about $274.2K of ALNY on Jun 1, 2026; 413 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 24, 2025.
- The trade is 31.0% of the 1,599 shares held after it.
- No other insider sold within 30 days.
- 413 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PYOTT DAVID E I sold about $148.9K of ALNY on Jun 1, 2026; 413 funds added in the latest 13F quarter.907 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.5M over 180 days
-$398.9K over 90 days
below 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
413 funds bought in last quarter
more than 97% of Pharma & Biotech
Revenue
+65.2% year over year
more than 80% of Pharma & Biotech
Margin
8.4% net margin
more than 80% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
5.8% of the float short (float per yahoo 2026-10-26) · 6.5 days to cover · settled 2026-09-30
more than 55% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 6EVP, CLO and Secretary SUPRAN BRYAN sold $398.9K (Oct 2)
Oct 2Officer SUPRAN BRYAN filed to sell $398.9K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch ALNY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-51.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ALNY: institutional holders (13F)
13F holdings, latest reported quarter
15,023,962 sh
$4.5B
11,144,846 sh
$3.4B
10,907,675 sh
$3.3B
9,750,699 sh
$2.9B
6,538,390 sh
$2.0B
Congress trades in ALNY
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-05-12 · disclosed 41 days later
$15,001 - $50,000
Sold 2024-01-29 · disclosed 17 days later
$1,001 - $15,000
Bought 2024-01-11 · disclosed 35 days later
$1,001 - $15,000
Sold 2023-12-11 · disclosed 27 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ALNY planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
SUPRAN BRYAN
Filed 2026-10-02
$398.9K
ALNY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VanEck Biotech ETF
$15.2M position · as of 2026-06-30
3.8%
Fidelity Advisor Biotechnology Fund
$79.6M position · as of 2026-07-31
3.6%
Horizon Kinetics Medical ETF
$652.6K position · as of 2026-06-30
3.4%
American Century Mid Cap Growth Impact ETF
$3.2M position · as of 2026-05-31
3.2%
Invesco Nasdaq Biotechnology ETF
$2.1M position · as of 2026-05-31
3.2%
Invesco Biotechnology & Genome ETF
$8.9M position · as of 2026-07-31
3.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
56 registered trials, 26 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
11
Phase 1
7 active
14
Phase 2
5 active
14
Phase 3
5 active
10
Not applicable
6 active
7
Multi-phase
3 active
What changed recently
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
2026-10-16 · Recruiting → Active Not Recruiting
Phase 1
A Study to Evaluate ALN-2232 in Participants With Obesity
2026-10-14 · Completion moved 2027-04-27 → 2027-04-28
PHASE1,PHASE2
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
2026-09-09 · Completion moved 2027-04-01 → 2030-12-31
,
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type
2026-09-09 · Completion moved 2028-09-01 → 2029-01-02
,
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
2026-09-04 · Recruiting → Active Not Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Alnylam Pharmaceuticals, Inc. Political Action Committee (Alnylam Pac)
Cycle 2026 · $178K spent
$149.7K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Yvonne L. Greenstreet, M.D.
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$14.9M
$77.4M
$6.6M
+206%
+25%
2024
$11.5M
$29.8M
$3.0M
+81%
-7%
2023
$8.9M
$11.4M
$2.9M
+47%
-6%
2022
$4.6M
$19.0M
$3.6M
+83%
-10%
2021
$10.2M
$17.5M
$5.9M
+30%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.5M sold by insiders over 180 days, 413 funds added last quarter, $398.9K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ALNY financials
Revenue growth
+65.2%
XBRL, annual
Net margin
8.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM ALNY
| FY Dec 2025 | $3.7B |
| FY Dec 2024 | $2.2B |
| FY Dec 2023 | $1.8B |
| FY Dec 2022 | $1.0B |
| FY Dec 2021 | $844.3M |
| Jun 2026 | $1.3B |
| Mar 2026 | n/a |
| Dec 2025 | $1.1B |
| Sep 2025 | $1.2B |
| Jun 2025 | $773.7M |
| Mar 2025 | $594.2M |
| Dec 2024 | $593.2M |
| Sep 2024 | $500.9M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM ALNY
| FY Dec 2025 | n/a |
| FY Dec 2024 | -12.4% |
| FY Dec 2023 | -24.1% |
| FY Dec 2022 | -109.0% |
| FY Dec 2021 | -101.0% |
| Jun 2026 | +12.7% |
| Mar 2026 | n/a |
| Dec 2025 | +10.2% |
| Sep 2025 | +20.1% |
| Jun 2025 | -9.3% |
| Mar 2025 | -3.1% |
| Dec 2024 | -14.1% |
| Sep 2024 | -22.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$465.4M
operating cash flow minus capex, 2025-01-01 to 2025-12-31
Free cash flow, TTM ALNY
| FY Dec 2025 | $465.4M |
| FY Dec 2024 | -$42.6M |
| FY Dec 2023 | $41.9M |
| FY Dec 2022 | -$613.3M |
| FY Dec 2021 | -$718.1M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $140.3M |
| Sep 2025 | $338.9M |
| Jun 2025 | $113.5M |
| Mar 2025 | -$127.3M |
| Dec 2024 | -$103.8M |
| Sep 2024 | $39.5M |
At each fiscal year end
Single quarter
Debt to equity
0.75x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity ALNY
| FY Dec 2025 | 1.28x |
| FY Dec 2024 | 15.27x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 1.15x |
| Jun 2026 | 0.75x |
| Mar 2026 | 1.28x |
| Dec 2025 | 1.28x |
| Sep 2025 | 4.45x |
| Jun 2025 | 1.85x |
| Mar 2025 | 2.41x |
| Dec 2024 | 15.27x |
| Sep 2024 | 31.64x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.52x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt ALNY
| FY Dec 2025 | 0.52x |
| FY Dec 2024 | -0.01x |
| FY Dec 2023 | 0.10x |
| FY Dec 2022 | -0.53x |
| FY Dec 2021 | -0.95x |
| Jun 2026 | 0.52x |
| Mar 2026 | 0.52x |
| Dec 2025 | 0.52x |
| Sep 2025 | 0.26x |
| Jun 2025 | -0.04x |
| Mar 2025 | -0.04x |
| Dec 2024 | -0.01x |
| Sep 2024 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on equity ALNY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -526.1% |
| FY Dec 2021 | -106.3% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +57.7% |
| Jun 2025 | -103.5% |
| Mar 2025 | -222.8% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets ALNY
| FY Dec 2025 | n/a |
| FY Dec 2024 | -6.9% |
| FY Dec 2023 | -11.9% |
| FY Dec 2022 | -31.5% |
| FY Dec 2021 | -24.2% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +1.7% |
| Jun 2025 | -6.7% |
| Mar 2025 | -5.7% |
| Dec 2024 | -6.9% |
| Sep 2024 | -8.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital ALNY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed ALNY
| FY Dec 2025 | +15.3% |
| FY Dec 2024 | -6.0% |
| FY Dec 2023 | -10.0% |
| FY Dec 2022 | -27.4% |
| FY Dec 2021 | -24.6% |
| Jun 2026 | n/a |
| Mar 2026 | +15.3% |
| Dec 2025 | +15.3% |
| Sep 2025 | +8.4% |
| Jun 2025 | -5.8% |
| Mar 2025 | -3.8% |
| Dec 2024 | -6.0% |
| Sep 2024 | -6.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing ALNY
| FY Dec 2025 | 201.85x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | 167.95x |
| Dec 2025 | 201.85x |
| Sep 2025 | 912.00x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$29.8B
market value at close 2026-10-26 on 2026-07-24 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value ALNY
| FY Dec 2025 | $51.9B |
| FY Dec 2024 | $30.4B |
| FY Dec 2023 | $24.2B |
| FY Dec 2022 | $29.4B |
| FY Dec 2021 | $20.1B |
| Jun 2026 | $39.2B |
| Mar 2026 | $43.2B |
| Dec 2025 | $51.9B |
| Sep 2025 | $59.3B |
| Jun 2025 | $42.4B |
| Mar 2025 | $35.0B |
| Dec 2024 | $30.4B |
| Sep 2024 | $35.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield ALNY
| FY Dec 2025 | +0.9% |
| FY Dec 2024 | -0.1% |
| FY Dec 2023 | +0.2% |
| FY Dec 2022 | -2.1% |
| FY Dec 2021 | -3.5% |
| Jun 2026 | +1.2% |
| Mar 2026 | +1.1% |
| Dec 2025 | +0.9% |
| Sep 2025 | +0.4% |
| Jun 2025 | -0.2% |
| Mar 2025 | -0.2% |
| Dec 2024 | -0.1% |
| Sep 2024 | +0.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing ALNY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.7B | $2.2B | $1.8B | $1.0B |
| Operating income | $501.6M | -$176.9M | -$282.2M | -$785.1M |
| Net income | $313.7M | -$278.2M | -$440.2M | -$1.1B |
| EPS (diluted) | 2.33 | -2.18 | -3.52 | -9.30 |
| Operating cash flow | $524.1M | -$8.3M | $104.2M | -$541.3M |
| Cash | $1.7B | $966.4M | $812.7M | $866.4M |
| Long-term debt | $1.0B | $1.0B | $1.0B | $1.0B |
SEC XBRL, fiscal years, as known on 2026-10-27
ALNY Stock Sonar score 5/7 axes
Find similar shapesCompareALNY ranks highest on institutional and government (92nd percentile) and growth (80th), and lowest on insider conviction (16th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ALNY filings, in plain words
Are Alnylam Pharmaceuticals insiders buying or selling ALNY?
In the 180 days to 2026-10-27, Alnylam Pharmaceuticals insiders were net sellers, a net $1.5M across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded ALNY?
Yes, but not in the year to 2026-10-27; the latest on record is a sale by Jefferson Shreve dated 2025-05-12.
Are there planned insider sales of ALNY?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $398.9K of stock; the latest, by SUPRAN BRYAN, was filed 2026-10-02.
Read the full summary
In the 180 days to 2026-10-27, Alnylam Pharmaceuticals insiders were net sellers of ALNY, a net $1.5M across purchases and sales reported on Form 4 by 2 sellers. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in ALNY, none in the last year; the latest on record is a sale by Jefferson Shreve dated 2025-05-12. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $398.9K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
